SEC Filing: BioXcel Therapeutics Files 8-K Disclosure
BioXcel Therapeutics filed a Form 8-K with the U.S. Securities and Exchange Commission on Thursday, October 30, 2026, disclosing corporate governance changes and asset transactions. Investors are monitoring the filing for material impacts on the life sciences firm's asset structure and executive team.